A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00290706
Recruitment Status : Terminated (Closed per Data Monitoring Committee due to toxicity & incomplete treatment of patients resulting in poor data.)
First Posted : February 13, 2006
Last Update Posted : August 12, 2016
Eli Lilly and Company
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Northwestern University

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Estimated Primary Completion Date : March 2018
  Estimated Study Completion Date : March 2019